Eight weeks before slaughter, 26 heifers, 2 calves, and 1 steer were implanted with licensed anabolic preparations at off-label injection sites. After slaughter, 24 of 31 implantation sites (77%) were detected. Residual pellets of Revalor H contained a mean of 42.9 mg trenbolone acetate (range 19.8-57.7 mg) and 4.6 mg (1.96-6.45 mg) estradiol, corresponding to 30% (19.8-57.7%) and 32.7% (14.0-46.6%) of the originally applied dose, respectively. In the tissue areas containing residual Revalor H pellets, total residues ranged from 14.8 mg to 12.6 mg trenbolone acetate, 41.7 mg to 1.45 mg trenbolone, and 11.1 mg to 3.39 mg estradiol. The outer tissue areas of the injection sites contained <2 mg hormones. The preparations Synovex H, Finaplix H, Implus S, and Component EC behaved similarly to Revalor H. Residues of Synovex Plus were low, whereas the Compudose silicone rubber contained 58.8% of the implanted dose, but left no significant tissue residues. If implantation sites are processed in meat manufacturing, international threshold levels of the respective substances will be exceeded in tons of meat products.
A nabolic sex hormones have been used as growth-promoting agents in farm animals for 4 decades. After the license of preparations containing the naturally occurring gestagen progesterone, the estrogen estradiol, or the androgen testosterone (or their esters) for use in cattle in the United States during the 1950s, xenobiotic substances were also registered. In 1968, the synthetic gestagen melengestrol acetate (MGA) was approved as a feed additive to increase weight gain in heifers; this was followed 1 year later by approval of the estrogenic substance zeranol, a nonsteroid resorcylic acid lactone derived from the fusarium toxin zearalenone. In 1986, the U.S. Food and Drug Administration (FDA) licensed trenbolone acetate, which is superior to the physiological hormone testosterone in terms of quantitative effectiveness. Its strong anabolizing ability contributes to its androgenic potential and to its antiglucocorticoid (1) and gestagen (2) side-effects. The conditions of approval were subject to compliance with Good Veterinary Practice (GVP), which, for anabolic agents, implies (1) that each hormone (pellet or feedstuff) is administered to animals in accordance with the manufacturer's instructions, which follow the legislation of the respective country; and (2) that each hormone injection site is discarded during slaughter, and that implants will not enter human food or animal feed.
The substances (except MGA) are licensed as implant preparations that must be injected hypodermically into the pinna of the ear. The implanted ear must be discarded after slaughter to avoid transition into the human or animal food chain. The use of implants is also restricted by the kind of animal, e.g., progesterone is not licensed for use in heifers, and testosterone propionate is not licensed for steers. In calves, testosterone and trenbolone are prohibited.
It was assumed that in countries having licensed anabolic agents abuse of implants (misplacement, overdosing by multiple application of implants, usage in nonauthorized types of animals or species) would be of minor interest, because legal measures are available. However, illegal injection of trenbolone in calves has been documented in Canada (3) . The extraordinarily high residue levels could hardly be explained by correct injection of licensed steer-or heifer-preparations into the ears of calves. In a study sponsored by the European Commission, imported beef from the Hormone Free Cattle (HFC) program was monitored. The HFC program was undertaken by the U.S. Department of Agriculture together with beef producers, and enabled export of a specified amount of beef to the European Union (EU), where an import ban prohibits marketing of regular beef from the United States and Canada. Results of that study (4) (5) (6) showed that 12% of 258 meat and liver samples were positive for MGA, trenbolone, or zeranol. In addition, DNA gender identification showed that 3 of the 19 meat samples containing MGA originated from male animals, even though treatment of male animals with MGA is not approved in the United States. Of 38 samples of calf meat, 7 contained trenbolone, and 4 of 7 samples of calf liver contained trenbolone alone or trenbolone + zeranol. These substances violate the HFC-status and are not licensed for use in calves.
Hence, compliance with GVP cannot be assumed. Even implantation into animal parts other than the ear cannot be ex-cluded because inadequate immobilization of the animal to gain unimpaired access to the ear might result in unintentional implantation in another site. Such an injection into an off-label site could severely impair food safety.
The present study examines potential misuse via off-label implantation and provides accurate data on residues of anabolic implant preparations in misplaced injection sites. These residues and anabolic preparations are monitored by liquid chromatography (LC) with diode array detection (DAD) as previously proposed (7) (8) (9) .
Experimental

Animal Experiments
Five Holstein-Friesian heifers were each injected in the neck with a single dose of Revalor H 8 weeks before slaughter. The exact site of injection was in the middle between shoulder and head, about 6 cm below the cervical spine. These basic conditions were modified in later experiments by variations in injection site, preparation, application time, and sexual status of the animal (Table 1) . To ensure precise injection, animals were confined in a head gate with their heads completely fixed to the lattice by ropes. All preparations were injected with original implanter pistols according to the manufacturer's instructions, except for the application site. After the prescribed application time, the animals were slaughtered at an EU-official slaughterhouse.
At the time of hormone treatment, the heifers were 77-99 weeks old with an average weight of 367 kg. The steer and the male and female calves weighed 389, 140, and 105 kg at age 102, 13, and 14 weeks, respectively. The animals were fed 2 kg hay per day and head and corn silage ad libidum. All animals were acquired from an approved livestock provider; a veterinary inspection ensured their health condition. The heifers were cycling and gynecologically intact.
Initial Blood Sampling
An initial blood sample was taken to screen for previous hormonal treatment. The plasma concentrations of trenbolone, zeranol, and MGA were measured by standardized enzyme immunoassay (EIA) kits (R-Biopharm, Darmstadt, Germany) described previously (10, 11) . Residues of the substances were below the detection limits of 43, 113, and 22 pg/mL, respectively. Plasma concentrations of progesterone, also determined by EIA (12) , corresponded to the estrus cycle. Results of the initial blood screening and the gynecologic investigation did not indicate previous use of anabolic sex hormones.
Preparations, Standards, and Reagents
The implant preparations used in this study are commercially available in the United States. Table 2 summarizes the properties of the products. The content was verified by LC-DAD, and identity of the active ingredients was confirmed by gas chromatography with mass spectrometric detection (GC/MS).
All standard material was purchased from ICN Biomedicals (Costa Mesa, CA; 16 α-methylprogesterone), Steraloids (Newport, RI; D-equilenin), or Sigma Chemical Co., (St. Louis, MO; all others). Standard identity was also confirmed by GC/MS, and purity was demonstrated by LC-DAD. All reagents were analytical grade and all solvents were of LC purity.
Residue Analysis
During slaughter, the entire misplaced implantation site, including surrounding tissues (1.5-3 kg), was excised from the carcass. At the laboratory, the injection site was prepared. The residue analysis refers to the visible remainder of the pellets (or silicone rubber), the inner tissue area that contains the injected pellets, and the outer area that surrounds the inner area. The residue analysis was performed by LC-DAD after liquid extraction and solid-phase cleanup. For the inner and outer areas, internal standardization was applied.
Preparation of Implantation Sites
The tissue that was collected at the slaughterhouse and contained the implants was systematically cut into small pieces with a maximum diameter of 5 mm. All detected implants from each site were collected in a single vial and analyzed as a whole. For preparation of the inner area that contained the implants, all tissue within ca 2.5 cm around the pellets was collected. The region surrounding the inner area (i.e., the next 1.5 cm of tissue attached to the inner area) was sampled as the outer area. To prevent contamination of the tissue samples by residual pellets, disposable scalpels were used to extract the implants. Thus, visible residues of the implanted preparations and about 50-150 g of both inner and outer tissue were collected. An exception was made at the external ear, where a 3 cm area of the pinna of the ear surrounding the injection site (including cartilage and skin) served as the inner area and the earground was the outer area. At the crown, no tissue was extractable because the pellets were adhering to the bone.
Extraction and Cleanup
(a) Inner and outer tissue areas.-Samples were coarsely crushed into small pieces and homogenized on a Miccra (Art moderne Labortechnik, Mühlheim, Germany) high-speed mixer system together with an equal amount of 67mM phosphate buffer, pH 7.2 (the pinna of the ear sample required twice the amount of buffer). After addition of internal standard, 8 g homogenized sample was extracted twice by tert butyl-methyl-ether (TBME) with agitation overnight. The extraction vials were centrifuged (850 × g, 15 min, 4°C) and frozen (-60°C). The extract was then decanted and evaporated. The residue was redissolved in 2 mL methanol, thoroughly shaken, and frozen (-60°C). After centrifugation (850 × g, 2 min, -10°C), the supernatant was diluted with 4.5 mL water. The solution was applied to an octadecyl-silica cartridge, which was washed twice with 1 mL (40%) methanol. The hormones were eluted with 1.5 mL methanol. The metha-nol was evaporated and the residue was redissolved in acetonitrile for LC analysis.
(b) Implants.-After addition of 8 mL water, the pellets (original and recovered) were extracted 3 times with 8 mL TBME according to the tissue samples. After evaporation of the combined ether phases, the residue was dissolved in 10.0 mL methanol. Aliquots (100 µL) of the solution were evaporated and redissolved in LC solvent.
Quantification of Residues by LC-DAD
The LC analysis was performed on a Beckman (Munich, Germany) LC system with a 250 × 4.0 mm reversed-phase column (Prontosil 120-5-C 18 H, 5.0 µm; Bischoff, Leonberg, Germany). The mobile phase was acetonitrile-20mM tris-acetate buffer, pH 7.2, (42 + 58, v/v, solvent A; or 70 + 30, v/v, solvent B). The separation was performed by running solvent A 20 min, and solvent B 19 min, followed by cleaning with 97% (v/v) acetonitrile (5 min) and equilibration with solvent A (10 min), all at a flow rate of 1 mL/min. Column temperature was set at 25°C. The system was calibrated by integration of the peak areas and a regression line (R 2 > 0.999) through 6 calibration points covering at least 1 decimal place. The peaks were identified by retention times and UV spectra. Tissue analyses were standardized by internal standard added to the sample before extraction, and correction of the measured analyte concentration by the fraction of recovered internal standard. Internal standard substances were testosterone acetate (for trenbolone acetate, estradiol benzoate, and testos- terone propionate); D-equilenine (d-1,3,5(19),6,8-estrapentane-3-ol-17-one; for trenbolone, estradiol, testosterone, and zeranol); and 16 α-methylprogesterone (for progesterone). Table 3 lists the retention times of the substances.
Method Validation
(a) Accuracy.-Accuracy was determined as recovery from fortified (spiked) blank sample material collected from the necks of control animals. All recoveries were determined for 3 different spike values (high, middle, and low expected hormone concentrations in inner and outer areas of the implantation site) in 5 (progesterone, zeranol) or 10 replicates (others) each. Table 4 shows absolute recoveries and recoveries after correction by the internal standard for analytes. The standard substances had mean (n = 10) absolute recoveries of 68.1% (range 52.9-66.3%; D-equilenine), 62.1% (56.0-65.2%; 16 α-methylprogesterone), and 63.1% (60.3-66.7%; testosterone acetate).
(b) Precision.-Precision is the closeness of agreement between results obtained by applying experimental procedure several times; it covers repeatability and reproducibility. This study validated repeatability conditions (i.e., analysis of identical test material in the same laboratory by the same operator using the same equipment within short intervals of time), because it was not necessary to perform the method in other laboratories with other equipment. Precision is calculated as the coefficient of variation (% CV) of the 10 (5) results (after standardization) obtained from accuracy experiments. The last column of Table 4 contains the coefficients of variation.
(c) Limits of determination, quantitation, and detection.-The smallest analyte for which the method was validated with the specified accuracy and precision is defined as the limit of determination (Table 4) . However, smaller concentrations to a limit of 10 ng/g could be quantitated, depending on the appearance of the chromatogram.
Residue Identity Checks by GC/MS
Analyte identity checks for all implants were performed by GC/MS of heptafluorobutyryl derivatives based on procedures described earlier (13, 14) . The possibility of detecting steroid esters by GC/MS without hydrolysis was recently shown for melengestrol acetate (11) .
For at least one of each kind of recovered implants, a purified aliquot (5 µL) of extract solution was diluted with 50 µL acetone, and derivatized with 20 µL heptafluorobutyric anhydride (HFBA). After evaporation, the sample was redissolved in 100 µL octane and 1 µL was injected into the GC/MS (Platform II, Micromass, Manchester, UK). Identification was based on specific retention times and mass spectra [electron impact ionization (EI), m/z 300-700]. The characteristic ions used for identification are presented in Table 5 .
Quality Assurance
A Quality Assurance System guaranteed the accuracy of the entire study. All laboratory procedures followed a Quality Assurance Manual. The status of Quality Assurance/Quality 
Results
Extraction of Residual Pellets from Implantation Sites
One complete dose of the implant preparations used in these experiments consisted of either 4, 7, 8, or 10 single pellets in a line (except Compudose, which is a single silicone rubber). Altogether, 31 implantations were performed, omitting implantation in the ear of animal 07981. Twenty-four application sites (77%) were detected by the presence of residual pellets. The number of recovered pellets was smaller (67%) because not all of the pellets of a respective preparation could be found. Table 6 lists the results of pellet extraction by different parts of the experiment. Individual numbers of recovered pellets for each animal are included in Table 7 .
The recovered pellets were predominantly embedded in connective tissue sheaths. Generally, the size of the pellets was smaller than that of the original, but sometimes the external shape was nearly intact. One pellet, located next to nearly intact pellets, was completely fluidized, but clearly detectable in a tissue sheath, i.e., the condition of the implant or the implanted pellets, respectively, varied between obviously intact and presumably dissolved completely. At some implantation sites, single pellets were found within areas of 3-4 cm in diameter, indicating pellet migration within the off-label implantation sites of that experiment.
Hormone Residues in Detected Pellets
Basic experiment: Revalor H.-After a single misplaced application of Revalor H 8 weeks before slaughter, the average amounts of parent compounds detectable in recovered pellets were 42.9 mg (range 19.8-57.5 mg) for trenbolone acetate and 4.6 mg (range 1.96-6.45 mg) for estradiol (n = 14). That finding corresponds to 30.0% (14.1-41.1) and 32.7% (14.0-46.6) recovery of the applied dose. Calculated recovery rates were even higher when detected residues were compared with the dose of hormones originally present in the recovered pellets. The similar range of residues after injection in necks and other misplacement sites is outstanding, i.e., the hormone residues are predominantly dependent on the number of pellets recovered. Application in the authorized location (pinna of the ear) resulted in clearly higher hormone residues of Revalor H (74.3 and 7.91 mg, corresponding to recoveries over 50%; Table 7) .
Variation in gender, age, and duration.-The use of Revalor H in calves (which is not licensed in the United States) causes residues similar to those found in heifers. For the steer, no statement is possible, because no pellets were found. When the implant was injected 4 weeks before slaughter, the recovery of mother compounds was higher [59.0 and 60.6 mg (or %) of the maximum dose in the pellets]. In the experiment with 3 applications (4, 12, and 20 weeks before slaughter), an assignment of detected pellets to certain applications was not possible in the carcass. It is presumed that after longer application periods the residues decrease.
Variation of the preparation.-Compudose is striking for its high recovery rate (15.0 mg of 25.7 mg estradiol), and Synovex Plus for its low recovery rate (6.3 and 6.5% in the detected pellets). However, because those were single observations, they must be regarded as exemplary. Synovex H, Finaplix H, Implus S, and Component EC behaved in a manner similar to Revalor H. Ralgro was not evaluated because the pellets were either completely dissolved or it was not possible to find them.
Hydrolysis of esterified steroids.-In the recovered pellets, a small fraction of trenbolone acetate was hydrolyzed to trenbolone-17β. The absolute residues of free trenbolone in all implantation sites of trenbolone acetate ranged from 0.01 to 0.12 mg (mean 0.06 mg, n = 21), corresponding to a fraction between 0.1 to 0.3% (mean 0.15%), with no distinctive difference between the preparations (Revalor H, Finaplix H, Synovex Plus) and different applications. Hydrolysis of estradiol benzoate and of testosterone propionate was not observed in the respective pellets.
Residues in Inner Areas around the Pellets
(a) Revalor H.-After application of Revalor H, residues of trenbolone acetate, trenbolone-17β, and estradiol were widely scattered in the inner areas around the recovered pellets. Trenbolone acetate ranged from 0.21 to 118 µg/g, trenbolone-17β from 0.58 to 19.0 µg/g, and estradiol from 11.1 to 3931 µg/g. Multiplication of the concentrations by the total sample masses resulted in the corresponding total amounts of residues, covering a factor of 1000. Trenbolone acetate residues were between 14.8 µg and 12.56 mg, trenbolone-17β between 41.7 µg and 1.45 mg, and estradiol between 11.1 µg and 3.93 mg. Values in the mg range seem to be outliers and can be easily explained: Before preparation of the implantation sites, the collected tissue area was intact and the implants were not visible. In order to locate the implants, the surrounding tissue had to be trenched. During the cutting, contacting of unknown pellets with the knife or scalpel could not be prevented. Thus, the surrounding tissue may have been contaminated by particles of the preparations. Compared with the residual pellets, relatively high amounts of hydrolyzed, free trenbolone-17β were apparent. When the sum of trenbolone acetate and trenbolone-17β is set as 100%, between 7.4 and 83% (mean of 36%) of the original substance was hydrolyzed (Table 8) .
(b) Other preparations.-In single observations, residue amounts of Finaplix H, Synovex H, Component EC, and Implus S were similar to those of Revalor H in the enclosing tissues. Marked degrees of hydrolysis of trenbolone acetate for Synovex Plus (84%), of testosterone propionate for Synovex H (17%), and of estradiol benzoate for Component EC and Implus S (8 and 11%) were apparent. Although the residual estradiol in the silicone rubber Compudose was relatively high (58.4%), the preparation did not cause particular estradiol levels in the rubber surrounding tissue. Synovex Plus was outstanding for its low residues. The zeranol implantation site could not be found (similar to 6 of 24 Revalor H implantations) and therefore cannot be evaluated.
Residues in Outer Areas around the Pellets
(a) Revalor H.-The outer areas of Revalor H implantation sites contained <2 µg trenbolone acetate (data not shown). Exceptions were represented by neck (07998; 5.3 µg), earground (07977; 20.3 µg), breast muscle (05810; 8.9 µg), and the implantation 28 rather than 56 days before slaughter (05809; 58.5 µg). Outlying levels might originate from inevitable contamination during preparation. Tissue concentrations were normally <10 ng/g, but ranged from 50 to 220 ng/g in the exceptions shown above. Free trenbolone-17β was detectable in 15 of the 24 samples, with mean tissue concentrations of 37 ng/g, resulting in mean total amounts of 6 µg. Only 6 of the outer areas of Revalor H implantation sites contained residues of estradiol above the detection limit. When detectable, its concentrations were 140 ng/g and its total amounts were 26 µg as a mean. (b) Other preparations.-The outer area of the Finaplix H implantation site was striking for its high residue levels of trenbolone acetate (13.8 µg/g or 677 µg, respectively) and trenbolone-17β (4.5 µg/g or 221 µg, respectively) as compared to its inner area and to other preparations. Synovex Plus caused low residues: 2.5 µg total trenbolone, of which 39% were hydrolyzed to trenbolone-17β, and 2.8 µg to estradiol benzoate. The residues of testosterone propionate (10.8 µg), free testosterone (3.6 µg), and estradiol benzoate (5.6 µg) after Finaplix H application were higher. For Compudose, Component EC, Implus, and Ralgro no hormone residues were detectable in the outer areas.
Discussion
Hormone Residues at Off-Label Implantation Sites
The implant preparations licensed as hormonal growth promoters are sustained release formulations designed for use in the outer ear. Substances injected into off-label sites clear about 8 weeks after application, with 30% (range 14-47%) recovered from the implantation sites. Our results were in agreement with those of absorption experiments from compressed pellets containing trenbolone acetate and estradiol. After injection into the base of the ear of sheep, the site produced a marked increase in plasma concentrations of estradiol and trenbolone even 15 weeks after implantation (15) . At 100 and 140 days after application into the external ear, residuals of 6 and 18% trenbolone acetate were found in the injection sites (16) 
Results obtained from studies with compressed pellets were compared with those using oily suspensions, which might be observed in illegal practice. At 14 days after injection of 44 mg 4-14 C-estradiol-17β into the neck muscle of heifers, only about 0.06% of the original radioactivity remained at or near the injection site (17) . However, after injection of oily suspensions of nonradioactive compounds, 1-16% 19-nortestosterone (18), <5% estradiol benzoate and 19-nortestosterone (19) , and 0.03% estradiol benzoate (20) were detected at injection sites, indicating that the type of preparation strongly affects retention in tissue. Compressed pellets, which were found to have longest efficiencies in the animal, are potentially harmful when ingested.
Hydrolysis of esterified steroids is negligible in residual pellets, but relevant in surrounding tissue areas. This finding confirms our common understanding of the effective mode of implanted steroid esters: as long as they are embedded in the implant they are inert, but split apart after migration into the circulation.
Residues in Meat and Meat Products
Compressed hormonal implant preparations injected into parts of the animal that are not discarded after slaughter can enter human food even after long periods of withdrawal. Eight weeks after implantation at off-label sites, about 75% of the applications can be identified by visible residual pellets. Combined preparations typically contain hormone residues of 50 mg androgen or gestagen plus 4 mg estrogen. The amounts in the tissue areas around the pellets are lower by a factor of 100-1000 and reach 20-600 µg. Total residues in the outer areas are 300 times lower than in the inner regions and do not exceed 2 µg. Consequently, a risk assessment of hormone residues in misplacement sites must focus on the detectable implanted preparations remaining.
International Threshold Levels for Hormone Residues
Residues of the synthetic compounds trenbolone and zeranol were judged by Joint FAO/WHO Expert Committee on Food Additives (JECFA) and adopted by the Codex Alimentarius in 1995 (21) . Based on acceptable daily intake (ADI) levels, maximum residue levels (MRL) were established for their residues in liver and muscle. Estradiol-17β, testosterone, and progesterone were reassessed by JECFA 1999 (22) . The full report has not yet been published, but the summary form is available. MRLs were not specified because it was thought that residues of veterinary drugs in animal tissues had a wide margin of safety for consumption in food if the drug was used in accordance with good veterinary practice. Table 9 summarizes the international threshold values.
Contamination of Meat and Meat Products by Implantation Sites
When implant preparations are misplaced or when the ears of legally treated animals are not discarded after slaughter, milligrams of hormone residues potentially enter human nutrition. By consuming complete implantation sites, the consumer ingests hormone amounts that can have acute effects. A key consideration is the fraction of misplaced implants that might pass postmortem food inspection and thus reach the consumer; however, that question is not answered by our experimental data. Because hypothetically misplaced implants are not visible at the surface of carcasses, the risk that they would not be detected during inspection is very high. Meat inspection does not focus on the detection of foreign objects in skeletal muscle, especially in valuable parts of the carcass. During our experiments, we were often unable to find misplaced implants during sample collection; whole tissue regions into which were injected implants had to be dissected completely to find the hormone pellets. Thus, hypothetical misplaced implantation sites may normally pass official meat inspection at the slaughterhouse. Although such implants might be detected during preparation of meat in the kitchen, this is not a reasonable solution to the problem for consumers.
Implantation sites that are industrially processed into meat products contaminate whole batches of the respective foodstuff (minced meat, sausages, etc.). The resulting hormone residues widely exceed established international threshold levels cited in Table 9 . The model calculations in Table 10 illustrate the impairment of meat products caused by implantation sites that reach the processing plants. In the described scenario, a typical implantation site of Revalor H is processed during meat production. Typical batch sizes are 30 kg for butcher-made and 600 kg for industrial products. In that instance, trenbolone acetate and trenbolone-17β are not differentiated. The model calculation can easily be adjusted to other conditions, such as other preparations or dosages. Additionally, if implantation sites are discarded but not physically exterminated, they will be rendered for the processing of animal feed. The respective drugs are not destroyed by the temperatures usually used during that process and become measurable even in fed animals (23) . Thus, the hormones might be recycled.
Conclusions
The present study emphasizes the importance of GVP. However, because observance of GVP cannot be assumed, regulatory authorities should consider the possibility of misuse of anabolic agents such as injection at off-label sites. Because of the harmful effects of misplaced implantations on food production, correct injection of the preparations must be ensured, if necessary, by means of official surveillance.
Techniques for implant preparation of compressed pellets are over 40 years old. However, because of the enormous economic benefit and the need to preserve natural resources, growth promoting of farm animals cannot simply be rejected. New research is needed to increase meat production with the help of technologies that will eliminate the risk of leaving significant hormone residues in the animal.
